| Assessment Status | Rapid Review Complete |
| HTA ID | 25003 |
| Drug | Nivolumab with Ipilimumab |
| Brand | Opdivo® with Yervoy® |
| Indication | Nivolumab (Opdivo®) with Ipilimumab (Yervoy®) is indicated for the first-line treatment of adult patients with unresectable or metastatic mismatch repair deficient or microsatellite instability-high colorectal cancer. |
| Assessment Process | |
| Rapid review commissioned | 08/01/2025 |
| Rapid review completed | 14/02/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Nivo+Ipi not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
